Literature DB >> 18826949

Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins.

Andreas Walker1, Claudia Skamel, Jolanta Vorreiter, Michael Nassal.   

Abstract

Virus capsids find increasing use as nanoparticulate platforms for the surface display of heterologous ligands, including as multivalent vaccine carriers. Presentation on the icosahedral hepatitis B virus capsid (HBcAg) is known to strongly enhance immunogenicity of foreign sequences, most efficiently if they are inserted into the dominant c/e1 B cell epitope, a surface-exposed loop in the center of the constituent core protein primary sequence. Even some complete proteins were successfully inserted but others, e.g. the outer surface protein A (OspA) of the Lyme disease agent Borrelia burgdorferi, impaired formation of capsid-like particles (CLPs). This difference can be rationalized by the requirement for the termini of the insert to fit into the predetermined geometry of the two acceptor sites in the carrier. We reasoned that cleavage of one of the two bonds connecting insert and carrier should relieve these constraints, provided the cleaved protein fragments remain competent to support the particle structure. Indeed, HBcAg CLPs containing a recognition site for tobacco etch virus (TEV) protease in the c/e1 loop remained intact after cleavage, as did CLPs carrying a 65-residue peptide insertion. Most importantly, in situ cleavage of a core-OspA fusion protein by coexpressed TEV protease strongly enhanced CLP formation compared with the uncleaved protein. These data attest to the high structural stability of the HBcAg CLP and they significantly widen its applicability as a carrier for heterologous proteins. This approach should be adaptable to any protein-based particle with surface-exposed yet sequence-internal loops.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826949      PMCID: PMC2662272          DOI: 10.1074/jbc.M805211200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

Review 1.  Are weak protein-protein interactions the general rule in capsid assembly?

Authors:  Adam Zlotnick
Journal:  Virology       Date:  2003-10-25       Impact factor: 3.616

2.  Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency.

Authors:  R B Kapust; J Tözsér; J D Fox; D E Anderson; S Cherry; T D Copeland; D S Waugh
Journal:  Protein Eng       Date:  2001-12

3.  Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy.

Authors:  J F Conway; N Cheng; A Zlotnick; P T Wingfield; S J Stahl; A C Steven
Journal:  Nature       Date:  1997-03-06       Impact factor: 49.962

4.  Mapping of homologous interaction sites in the hepatitis B virus core protein.

Authors:  S König; G Beterams; M Nassal
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  Quaternary structure is critical for protein display on capsid-like particles (CLPs): efficient generation of hepatitis B virus CLPs presenting monomeric but not dimeric and tetrameric fluorescent proteins.

Authors:  Maren Vogel; Jolanta Vorreiter; Michael Nassal
Journal:  Proteins       Date:  2005-02-01

6.  Assembly of bacteriophage Qbeta virus-like particles in yeast Saccharomyces cerevisiae and Pichia pastoris.

Authors:  Janis Freivalds; Andris Dislers; Velta Ose; Dace Skrastina; Indulis Cielens; Paul Pumpens; Kestutis Sasnauskas; Andris Kazaks
Journal:  J Biotechnol       Date:  2006-01-06       Impact factor: 3.307

7.  Identification of hepatitis B virus core protein regions exposed or internalized at the surface of HBcAg particles by scanning with monoclonal antibodies.

Authors:  P Pushko; M Sallberg; G Borisova; U Ruden; V Bichko; B Wahren; P Pumpens; L Magnius
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

8.  Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.

Authors:  Kazunari Kondo; Hiroyuki Ochi; Tamae Matsumoto; Hiroyuki Yoshikawa; Tadahito Kanda
Journal:  J Med Virol       Date:  2008-05       Impact factor: 2.327

9.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen.

Authors:  D R Milich; A McLachlan
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

10.  A viral nanoparticle with dual function as an anthrax antitoxin and vaccine.

Authors:  Darly J Manayani; Diane Thomas; Kelly A Dryden; Vijay Reddy; Marc E Siladi; John M Marlett; G Jonah A Rainey; Michael E Pique; Heather M Scobie; Mark Yeager; John A T Young; Marianne Manchester; Anette Schneemann
Journal:  PLoS Pathog       Date:  2007-10-05       Impact factor: 6.823

View more
  11 in total

1.  A Tyr residue in the reverse transcriptase domain can mimic the protein-priming Tyr residue in the terminal protein domain of a hepadnavirus P protein.

Authors:  Jürgen Beck; Michael Nassal
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

Review 2.  Use of hepadnavirus core proteins as vaccine platforms.

Authors:  David C Whitacre; Byung O Lee; David R Milich
Journal:  Expert Rev Vaccines       Date:  2009-11       Impact factor: 5.217

3.  Conformational dynamics inside amino-terminal disease hotspot of ryanodine receptor.

Authors:  Xiaowei Zhong; Ying Liu; Li Zhu; Xing Meng; Ruiwu Wang; Filip Van Petegem; Terence Wagenknecht; S R Wayne Chen; Zheng Liu
Journal:  Structure       Date:  2013-10-17       Impact factor: 5.006

4.  SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure.

Authors:  Andreas Walker; Claudia Skamel; Michael Nassal
Journal:  Sci Rep       Date:  2011-06-14       Impact factor: 4.379

5.  Whole-Chain Tick Saliva Proteins Presented on Hepatitis B Virus Capsid-Like Particles Induce High-Titered Antibodies with Neutralizing Potential.

Authors:  Philipp Kolb; Reinhard Wallich; Michael Nassal
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

6.  Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.

Authors:  Jens Schumacher; Tijana Bacic; René Staritzbichler; Matin Daneschdar; Thorsten Klamp; Philipp Arnold; Sabrina Jägle; Özlem Türeci; Jürgen Markl; Ugur Sahin
Journal:  J Nanobiotechnology       Date:  2018-04-13       Impact factor: 10.435

7.  Hepatitis B virus core protein phosphorylation: Identification of the SRPK1 target sites and impact of their occupancy on RNA binding and capsid structure.

Authors:  Julia Heger-Stevic; Peter Zimmermann; Lauriane Lecoq; Bettina Böttcher; Michael Nassal
Journal:  PLoS Pathog       Date:  2018-12-19       Impact factor: 6.823

8.  Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Authors:  Milena Lange; Melanie Fiedler; Dorothea Bankwitz; William Osburn; Sergei Viazov; Olena Brovko; Abdel-Rahman Zekri; Yury Khudyakov; Michael Nassal; Paul Pumpens; Thomas Pietschmann; Jörg Timm; Michael Roggendorf; Andreas Walker
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

Review 9.  Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.

Authors:  Michela Perotti; Laurent Perez
Journal:  Viruses       Date:  2019-12-28       Impact factor: 5.048

10.  Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system.

Authors:  Hadrien Peyret; Daniel Ponndorf; Yulia Meshcheriakova; Jake Richardson; George P Lomonossoff
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.